Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
March 30, 2022 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
March 07, 2022 06:15 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
March 02, 2022 17:18 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer
February 22, 2022 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
February 01, 2022 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for...
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
January 27, 2022 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)...
Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences
December 22, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
December 09, 2021 08:30 ET
|
Acer Therapeutics Inc.
Phase 2a trial initiation expected in Q1 2022 Trial designed to generate proof of concept data for ACER-801 and identify optimal dose for subsequent efficacy trials in patients with iVMS NEWTON,...
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
November 19, 2021 17:00 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation
October 26, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF,...